Related Experiment Videos
A phase II study of tamoxifen in ovarian cancer
European Journal of Cancer & Clinical Oncology
|March 1, 1986
Abstract:
A phase II study of tamoxifen was conducted in 22 patients with stage III and IV ovarian cancer who had failed chemotherapy and who had evaluable disease. Tamoxifen was administered at a dose of 20 mg twice daily continuously until evidence of progression. Twenty-one patients had progression of disease within 3 months and one patient had stable disease for 6 months. There were no objective responses to this treatment.
Insights
This phase II study evaluated tamoxifen for advanced ovarian cancer. The drug showed no objective responses in patients who had previously failed chemotherapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced ovarian cancer (Stage III and IV) presents a significant treatment challenge, particularly after failure of standard chemotherapy.
- Identifying effective salvage therapies is crucial for improving outcomes in patients with refractory ovarian cancer.
Purpose of the Study:
- To assess the efficacy of tamoxifen as a salvage therapy in patients with advanced ovarian cancer who had progressed on prior chemotherapy.
- To determine objective response rates and disease control in this heavily pre-treated patient population.
Main Methods:
- A phase II clinical trial was conducted involving 22 patients with Stage III and IV ovarian cancer.
- Patients received tamoxifen at a dose of 20 mg twice daily continuously until disease progression.
- Eligibility criteria included evaluable disease and prior failure of chemotherapy.
Main Results:
- Twenty-one out of 22 patients (95%) experienced disease progression within 3 months of treatment initiation.
- One patient (5%) achieved stable disease for 6 months.
- No objective responses (complete or partial) were observed in any of the participants.
Conclusions:
- Tamoxifen, at the tested dose and schedule, demonstrated minimal efficacy as a salvage treatment for patients with advanced ovarian cancer who had failed prior chemotherapy.
- Further investigation into tamoxifen for ovarian cancer may require different patient selection or combination strategies.